Skip to main content

Table 14 The cost-effectiveness analysis in the 24-month period (reversion rate)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group

C(yuan)

E (%)

C/E

ΔC/ΔE

The treatment group

41367830.8

45.1

917246.8

 

The control group

37529823.2

30

1250994.1

254172.7